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Supplemented very low protein diet ameliorates responsive-
ness to erythropoietin in chronic renal failure.
Background. The aim of this study was to evaluate the rela-
tionship between uremic state and erythropoiesis in patients
with predialytic chronic renal failure (CRF).
Methods. We monitored for 2 years the erythropoietin
(EPO) requirement in patients with advanced CRF (creatinine
clearance25 mL/min), randomized to either low protein diet
(LPD) group (0.6 g/kg body weight/day, N  10) or very low
protein diet (VLPD) group (0.3 g/kg body weight/day, N 
10) supplemented with a mixture of ketoanalogs and essential
amino acids, both kept at target hemoglobin levels.
Results. The achieved protein intake after 6 months was
0.79  0.02 g/kg body weight/day and 0.50  0.02 g/kg body
weight/day in LPD and VLPD, respectively; such a difference
was maintained up to the end of follow up. The final hemoglo-
bin values did not differ from the basal values in either group
(11.5  0.2 g/dL and 11.5  0.3 g/dL). EPO dose, that was
similar at baseline (62.4  9.6 UI/kg body weight/week and
61.8 8.8 UI/kg body weight/week subcutaneously), remained
unchanged in LPD but progressively decreased in VLPD down
to the final value of 41.2  7.0 UI/kg body weight/week (P 
0.0001 vs. basal and LPD). VLPD was associated with a de-
crease of urinary excretion and serum levels of urea nitrogen
and phosphate; however, EPO requirement was not correlated
with the changes of these parameters. On the contrary, the
variation of EPO dose directly correlated with the modification
of parathyroid hormone (PTH) levels, that diminished from
229  55 pg/mL to 118  16 pg/mL (P  0.0001) in VLPD
and did not change in LPD.
Conclusion. In patients with advanced CRF, an effective
decrease of protein intake of 0.3 g/kg body weight/day induces
a reduction of about 35% of the EPO dose required to maintain
the target hemoglobin levels. This effect appears dependent on
the correction of a moderate secondary hyperparathyroidism.
Anemia is a major complication of dialytic and predia-
lytic stages of chronic renal failure (CRF). In predialysis
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CRF patients, the International Guidelines recommend
administration of erythropoietin (EPO) at dosage ade-
quate to reach and maintain the hemoglobin level at the
same target indicated for dialysis patients [1, 2]. Indeed,
the major benefits of anemia correction on quality of
life, cardiovascular outcome, and mortality are now well
recognized, and, moreover, clinical studies have ex-
cluded the hypothesized worsening effect of EPO on
progression of renal disease [3–5]. Nevertheless, the im-
plementation of the guidelines on anemia correction in
predialysis remains scarce [6, 7]. Effort must be therefore
made to improve the control of anemia in this large
subgroup of CRF patients.
Both experimental and clinical studies have generated
evidence that the uremic state inhibits erythropoiesis
[8–11]. Specifically, in hemodialysis patients treated with
a fixed dose of EPO, an urea reduction ratio 65% is
associated with a low hematocrit value that augments
after increasing the efficiency of hemodialysis treatment
[10]. On the other hand, inpatients constantly maintained
at hematocrit values of 35% by EPO treatment, Kt/V
and EPO dose are inversely correlated [11]. On the basis
of these observations in hemodialysis, one may hypothe-
size that better control of uremia ameliorates respon-
siveness to EPO also in prehemodialysis patients.
It is well known that protein-restricted diets reduce
signs and symptoms of uremia in CRF patients. In addi-
tion, the Modification of Diet in Renal Disease (MDRD)
and recent metabolic studies have documented that the
efficacy of either low protein diet (LPD) or very low
protein diets (VLPD) is not weakened by detrimental
effects on nutritional status [12–16]. More important, the
dietary approach has been found efficacious in delaying
the initiation of hemodialysis treatment [14, 16]. Despite
the proven efficacy of dietary protein restriction in con-
trolling uremia in pre hemodialysis patients, the potential
impact of this effect on erythropoiesis has never been
assessed. In patients with predialytic CRF, we therefore
evaluated, by means of a prospective long-term study,
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the effect of a supplemented VLPD, as compared with
standard LPD, on the requirement of EPO needed to
maintain hemoglobin levels within the recommended
range.
METHODS
Study population
In our outpatient clinic for the conservative treatment
of CRF, we selected patients with creatinine clearance
25 mL/min/1.73 m2 and treated with LPD (0.6 g/kg
body weight/day) and EPO for a period of 6 to 12 months.
Patients with bleeding or diseases potentially affecting
EPO response, such as neoplastic diseases, infectious
diseases, and severe malnutrition, were excluded. Out
of a pool of 33 eligible patients, 20 gave their informed
consent to the study. These 20 patients were therefore
randomized into two groups; one group started a VLPD
supplemented by ketoanalogs and essential amino acids
(N  10), while the remaining patients continued their
usual LPD and constituted the control group (N  10).
Treatment regimens
The LPD provided 0.6 g of protein/kg body weight/
day with a caloric intake of 35 kcal/kg body weight/day,
while the VLPD supplied the same caloric intake but
with 0.3 g/kg body weight/day of protein of vegetable
origin. This diet was supplemented with a mixture of
ketoanalogs and essential amino acids (Alfa Kappa) (Ke-
drion, Lucca, Italy) administered at the dose of 1 tablet/
5 kg body weight; each tablet contained calcium keto-
isoleucine 67 mg, calcium keto-leucine 101 mg, calcium
phenylpyruvate 68 mg, calcium keto-valine 86 mg, calcium
hydroxy-methionine 59 mg, l-lysine monoacetate 105 mg,
l-threonine 53 mg, l-histidine 38 mg, and l-tyrosine 30 mg.
All patients were required to restrict their dietary sodium
intake.
Study design
Prior to randomization, we performed a 3 month run-
in period in order to verify the stability of hemoglobin
coefficient of variation (3%). Follow-up on the diets
lasted 24 months. Patients were seen every month to
measure renal function, hemoglobin levels, adherence
to dietary prescription, and blood pressure. For the sta-
tistical analysis, we used the data at the 6-month interval.
The patient terminated the study if the value of creati-
nine clearance decreased to  7 mL/min/1.73 m2 or be-
cause of development of uremic complications requiring
hemodialysis treatment.
Pharmacologic treatment
EPO therapy (-epoietin) was administered subcuta-
neously once a week and the dose was adjusted in each
patient to maintain hemoglobin levels in the 11 to 12
g/dL range. Iron supplementation was performed to keep
tranferrin saturation (TSAT) 20% and serum ferritin
between 100 and 500 mg/dL. Antihypertensive therapy
was administered in all patients to maintain blood pres-
sure levels 140/90 mm Hg. Patients also received 2 to
3 g/day of sodium bicarbonate and folic acid/vitamin B12
supplements. Phosphate binders were administered to
maintain serum phosphate levels  5.5 mg/dL.
Measurements
Blood pressure was measured by mercury sphygmo-
manometer, with the first and fifth Korotkoff sounds
being used to identify systolic and diastolic blood pres-
sure, respectively. The reported values were the mean
of three consecutive measurements obtained after 15
minutes of rest. Serum albumin, serum and urinary levels
of creatinine, urea, sodium, phosphate, and potassium
were measured by an autoanalyzer (Olympus AU 400)
(Olympus Italia, Segrate, Italy). Dietary protein intake
was estimated from 24-hour urea N excretion according
to Maroni, Steinman, and Mitch [17]. To determine the
dietary energy intake, patients recorded on dietary dia-
ries the amount of ingested food and the daily number
of meals (breakfast, lunch, dinner, and snacks) once each
month. A skilled dietitian trained patients how to record
the total food intake in the diary by household measures,
and also instructed them to take the measures of the
utensils before starting food record. The same person
analyzed all food records over the study period, comput-
ing dietary protein and energy intake.
Hemoglobin was measured by Coulter counter (Coulter
Electric, Hialeah, FL, USA). Three different amounts
of hemoglobin standards (8.2, 13.2, and 15.5 g/dL) were
analyzed during the analytic session to evaluate the sta-
bility of the method. Analysis of hemoglobin standards
was performed during the single analytic session and
over the study time. Results are expressed as coefficient
of variation 1.1%, 1.1%, and 1.2% for 8.2, 13.2, and
15.5 g/dL standards for daily variation. Iron and trans-
ferrin values were obtained by automated methods.
TSAT was calculated by means of the following formula:
TSAT%  [plasma iron (g/dL)/transferrin (mg/dL) 
1.41]  100. The ferritin value was determined by en-
zyme-linked immunosorbent assays (ELISA). The para-
thyroid hormone (PTH) level was assessed by standard
radioimmuno assay (RIA) method using two affinity-
purified goat antibodies specific for two different regions
of the PTH molecule (PTH 1-34; and PTH 39-84) (Sorin,
Saluggia, Italy). C-reactive protein (CRP) was quantified
by nephelometry by using a BNA II Nephelometer
(Dade Behring, Inc., Newark, DE, USA).
Patients were trained to correctly collect 24-hour
urine. The collection was considered incomplete if total
volume was less than 750 mL and creatinine excretion
was less than 10 mg/kg body weight.
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Statistical analysis
All the values are reported as mean  SD. Analysis
of variance (ANOVA) for repeated measures followed
by the Newman Keuls as post hoc test and paired Student
t test were used for intragroup statistical analysis. Un-
paired Student t test was used for intergroup compari-
sons. Fisher’s exact test was used to compare categorical
variables. Correlations between individual parameters
were evaluated using linear regression analysis. A two-
tailed P value  0.05 was considered significant. The
primary efficacy variable considered to calculate the sam-
ple size was the percent reduction (versus baseline) of
the EPO dose. A mean basal EPO dose of 65.3  10.6
IU/kg body weight/week was detected in the eligible
patients with CRF attending our outpatient clinic. Con-
sidering as clinically relevant a reduction of 30%, we
predicted a decrease of EPO dose from 65.3 to 45.7.
Thus, it was estimated that to give the study a 90% power
to have such a difference as statistically significant (P 
0.05), a minimum sample size of eight patients in each
group was required.
RESULTS
The two study groups, LPD and VLPD, did not sig-
nificantly differ for gender distribution (six males and
four females in each group), age (52  15 years vs. 57 
17 years, respectively) and body mass index (23.5  1.4
kg/m2 vs. 23.2  1.1 kg/m2, respectively). Similarly, the
systolic and diastolic blood pressure values did not sig-
nificantly differ at baseline (135  17/87  5 mm Hg
and 131  12/86  4 mm Hg, respectively). In the LPD
and VLPD groups, the underlying renal disease was,
respectively, diabetic nephropathy (N 3 and 3), tubulo-
interstitial nephropathy (N 3 and 0), glomerulonephri-
tis (N  2 and 3), hypertensive nephropathy (N  1 and
1), and unknown (N  1 and 3).
The duration of follow-up was significantly longer in
VLPD than LPD (23.2  1.9 months vs. 19.6  4.0
months, respectively, P  0.02); in VLPD, in fact, eight
out ten patients completed the 24-month period of fol-
low-up, while seven out ten patients of the LPD group
stopped the study after month 18 having reached the
end point. Therefore, we did not perform statistical anal-
ysis of the LPD data at month 24 (N  3).
At baseline, in VLPD and LPD, EPO dose was 61.8
8.8 U/kg body weight/week and 62.4  9.6 U/kg body
weight/week, and hemoglobin levels were 11.5 0.3 g/dL
and 11.5 0.2 g/dL, respectively. The hemoglobin values
remained unchanged during the follow-up in both groups,
being 11.4  0.2 g/dL in VLPD at month 24 and 11.6 
0.2 g/dL in LPD at month 18. The pattern of changes of
EPO dose and hemoglobin levels in VLPD and LPD is
Fig. 1. Erythropoietin (EPO) dose (bars) and hemoglobin concentra-
tion (line) at baseline and during follow-up in very low protein diet
(VLPD) (A ) and low protein diet (LPD) (B ) patients. In VLPD, at
24 months, data refer to eight patients; in LPD, at 18 months, data
refer to nine patients. *P  0.05 vs. baseline; #P  0.05 vs. following
point.
reported in Figure 1. In this group, EPO requirement
progressively decreased during the first year, reaching a
plateau at 18 months; EPO dose, in fact, was reduced
down to 56.1  9.0, 47.5  8.3, 41.5  6.4, and 41.2 
7.0 after 6, 12, 18, and 24 months, respectively. On the
contrary, EPO requirement in LPD did not differ through-
out the study from baseline, being 65.4 10.8 U/kg body
weight/week at month 18.
The markers of compliance to dietary prescription are
depicted in Table 1. During follow-up, dietary energy
intake remained constantly above 30 kcal/kg/day in both
groups. In VLPD, a stable reduction of daily excretion
of urinary urea nitrogen became manifest within the
initial 6 months; this corresponded to a decrease of pro-
tein intake from 0.81  0.02 g/kg body weight/day to
0.50  0.02 g/kg body weight/day. The reduced protein
intake was coupled with the decline of blood urea nitro-
gen and serum and urinary phosphate levels. On the
contrary, no major change of these parameters was de-
tected in LPD. No correlation was found between the
percentual change of blood urea nitrogen or serum phos-
phate and EPO dose at any time interval. At baseline,
the mean values of serum calcium levels were similar
between VLPD and LPD (9.4  0.7 mg/dL and 9.5 
0.5 mg/dL, respectively) and did not change throughout
the study.
In Table 2, we report the values of the main markers
associated with EPO responsiveness. In both groups, the
mean values of body weight and serum albumin did not
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Table 1. Indexes of compliance to dietary prescription in very low protein diet (VLPD) and low protein diet (LPD) patients
Baseline 6 months 12 months 18 months 24 months
VLPD
Patients number 10 10 10 10 8
BUN mg/dL 8213a 4310b 419b 428b 447
UUN g/day 6.520.85a 3.210.37b 3.220.42b 3.200.40b 3.140.37
Serum phosphate mg/dL 3.70.8a 3.20.2b 3.20.3b 3.20.3b 3.10.2
Urinary phosphate mg/day 808178a 503122b 518143b 492155b 48695
DPI g/kg/day 0.810.02 0.500.02b 0.500.01b 0.490.02b 0.490.02b
LPD
Patients number 10 10 10 9 3
BUN mg/dL 897 8711 8610 849 —
UUN g/day 6.350.64 6.260.73 6.250.74 6.260.76 —
Serum phosphate mg/dL 3.80.4 3.90.3 4.00.4 4.10.5 —
Urinary phosphate mg/day 826212 830183 815216 794159 —
DPI g/kg/day 0.800.01 0.790.02 0.790.02 0.790.02 —
Abbreviations are: BUN, blood urea nitrogen; UUN, urinary urea nitrogen; DPI, dietary protein intake. The values are meanSD.
a P  0.001 vs. following points; bP  0.05 vs. LPD
Table 2. Markers of conditions associated with resistance to erythropoietin (EPO) in very low protein diet (VLPD)
and low protein diet (LPD) patients
Baseline 6 months 12 months 18 months 24 months
VLPD
Patients number 10 10 10 10 8
Body weight kg 66.78.9 66.78.9 66.68.8 66.78.7 66.78.7
ALB g/dL 3.90.1 3.90.2 3.90.3 4.00.2 3.90.1
TSAT % 305 296 317 297 306
Serum ferritin ng/mL 23652 23482 21955 23265 22572
PTH mg/dL 22955a 16839b,c 12718b 12420b 11816
CRP lg/mL 0.800.26 0.660.20 0.720.30 0.600.25 0.600.21
LPD
Patients number 10 10 10 9 3
Body weight kg 65.87.3 65.97.2 65.97.2 65.67.5 —
ALB g/dL 4.00.3 4.10.2 4.10.2 4.00.2 —
TSAT % 314 304 324 337 —
Serum ferritin ng/mL 25688 23797 257103 23276 —
PTH mg/dL 21352 22952 21636 21837 —
CRP lg/mL 0.720.22 0.700.20 0.750.24 0.720.25 —
Abbreviations are: ALB, serum albumin; TSAT, total saturation of transferrin; PTH, parathyroid hormone; CRP, C-reactive protein. The values are meanSD.
aP  0.001 vs. following points; bP  0.05 vs. LPD; cP  0.05 vs. following points
change during the follow-up and between the two groups.
Iron status was adequate in the two groups of patients;
indeed, in our patients, iron was regularly administered
to maintain the values of serum ferritin and total TSAT
within the recommended range in VLPD and LPD
throughout the study. Similarly, development of in-
flammatory status could be excluded on the basis of
normal values of CRP. In contrast, PTH progressively
decreased in VLPD patients; the reduction was of 25%
15% after 6 months and doubled by month 12 (42%
16%, P  0.005), remaining constant thereafter (Table
2). On the contrary, in LPD, PTH concentration did
not vary during the whole study period (Table 2). As
depicted in Figure 2, the percentage changes of PTH
and EPO dose at month 18 were directly correlated (N
19, r  0.762, P  0.0001). This correlation remained
highly significant at month 12 (N  20, r  0.661, P 
0.0015) and at month 24 (N  11, r  0.666, P  0.025).
Fig. 2. Linear regression between the percentage changes of parathy-
roid hormone (PTH) level and erythropoietin (EPO) dose at 18 months
in low protein diet (LPD) and very low protein diet (VLPD) patients
(N  19, r  0.762, P  0.0001).
Di Iorio et al: VLPD ameliorates responsiveness to EPO in CRF1826
Table 3. Main clinical parameters in very low protein diet (VLPD) and low protein diet (LPD) patients at baseline and during follow-up
Baseline 6 months 12 months 18 months 24 months
VLPD
Patients number 10 10 10 10 8
Creatinine clearance mL/min/1.73 m2 15.44.2 15.74.9 15.76.4 15.66.6 18.54.7
Mean arterial pressure mm Hg 1037a 966 958 9610 917
Urinary sodium mEq/day 17022a 13820b 14718b 13916b 13016
Triglycerides mg/dL 18020a 15117b 15010b 14512b 14815b
Cholesterol mg/dL 20147a 17220 15917b 15716b 15816
LPD
Patients number 10 10 10 9 3
Creatinine clearance mL/min/1.73 m2 17.33.5a 16.24.0a 14.25.1a 12.45.3 —
Mean arterial pressure mm Hg 1014 995 996 984 —
Urinary sodium mEq/day 17124 16824 16519 16622 —
Triglycerides mg/dL 17521 17819 17330 18021 —
Cholesterol mg/dL 19829 18727 19019 20626 —
The values are meanSD.
aP  0.01 vs. following points; bP  0.05 vs. LPD
As shown in Table 3, the decline of renal function was
greater in the latter group (0.30 0.16 mL/min/month)
with respect to VLPD patients (0.01  0.22 mL/min/
month, P  0.003). Arterial blood pressure was ade-
quately controlled in the two groups of patients with
no value exceeding 140/90 mm Hg. Of note, in VLPD
patients, mean arterial pressure significantly decreased
during follow-up, while no significant change was de-
tected in LPD; in addition, urinary sodium excretion
significantly decreased during follow up in VLPD but
not in LPD patients (Table 3). Similarly, plasma triglyc-
erides and cholesterol decreased in VLPD group but not
in LPD.
DISCUSSION
This study demonstrates that in patients with advanced
CRF, a supplemented VLPD, as compared with a stan-
dard LPD, allows a long-lasting reduction of the EPO
dose required to maintain hemoglobin level within the
recommended range. This favorable effect on EPO resis-
tance was determined by an achieved reduction in di-
etary protein intake of 0.3 g/kg body weight/day, that is,
from 0.8 to 0.5 g/kg body weight/day. The study provides
first-time evidence on the beneficial effects of protein
restriction on anemia management of advanced CRF
since all the early works on uremic patients have exclu-
sively focused on the outcome of renal function and/or
nutritional status [12–16, 18, 19].
To assess the isolated effect of dietary protein intake,
we planned a careful control of the main determinants
of resistance to EPO. It is well known that the response
to EPO in predialytic CRF can be improved by some
standard interventions, iron replacement being the most
important one. During follow-up, serum ferritin and total
TSAT remained constantly within the recommended
range in VLPD and LPD patients by adequate adminis-
tration of iron. Deficiencies of folate and vitamin B12
were avoided by periodic supplementation. The absence
of malnutrition, that is, an uncommon cause of anemia
in predialysis, was indicated by constancy of body weight
and of normal values of serum albumin during the entire
follow-up; indeed, dietary energy intake remained con-
stantly above 30 kcal/kg body weight/day. Therefore, we
can reasonably exclude that all these factors played a
role in the different response to EPO.
On the contrary, the improvement of EPO response
in VLPD was associated with a stable correction of the
uremic state, as testified by the marked decrease of blood
urea nitrogen. In uremic patients, Ifudu, Feldman, and
Friedman [10] have demonstrated that an increase of
dialytic dose is associated with increment of hemoglobin
levels; however, the authors did not provide insights into
the underlying pathophysiology. On this regard, experi-
mental studies have shown that the substances exacerbat-
ing anemia in renal failure are of middle molecular
weight [8, 9]. When serum drawn from an uremic patient
is added to cultured bone marrow erythroid cells, a dose-
dependent inhibition of the cell growth ensues; this ef-
fect, however, is not due to urea per se, since this sub-
stance does not possess inhibitory activity in vitro [8, 9].
The current clinical data tend to confirm these experi-
mental findings; we did not detect in fact any correlation
between EPO dose and blood urea nitrogen. Similarly,
no correlation was found between EPO dose and phos-
phate levels. Finally, we can reasonably exclude that
proinflammatory cytokines, which contribute to the
pathogenesis of anemia in hemodialysis patients [20],
may have played a role; in fact, the serum values of CRP
were constantly normal in both LPD and VLPD patients
throughout the study.
Interestingly, our long-term, prospective and con-
trolled study demonstrates that, in agreement with previ-
ous short-term or retrospective or not-controlled works
[21, 22, 23], supplemented VLPD decreases the serum
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concentration of phosphate and, consequently, PTH lev-
els. Experimental studies have shown an inhibitory effect
of PTH on erythropoiesis [24, 25]. Furthermore, amelio-
ration of responsiveness to EPO by parathyroidectomy
or intravenous administration of calcitriol has been
shown in hemodialysis patients affected by severe hyper-
parathyroidism [26, 27]. Despite this, the potential rele-
vance of PTH to renal anemia has never been evaluated
in prehemodialysis renal failure. In the present study, a
strict correlation was found between the reduction of
EPO dose and PTH, suggesting that the improvement
of responsiveness to EPO was mediated by the correction
of an even moderate hyperparathyroidism, secondary to
the restriction of dietary phosphate intake. Nevertheless,
we cannot exclude that the calcium salts of the keto-
analogous preparation may have at least in part acted
as intestinal phosphate-binding agent [21, 22]. Actually,
the progressive decrease of EPO dose requirement in
VLPD group paralleled the time-course reduction of
PTH levels. Thus, the changes in EPO responsiveness
may be the expression of a functional phenomenon re-
lated to the slow, progressive decline of PTH availability.
This relationship between EPO dose and PTH values
has been sought but not found in hemodialysis patients
[11, 28]. The discrepancy with our data may be related
to the major contribution of factors other than PTH in
determining the degree of anemia in the dialytic phase
of CRF; under this condition, in fact, the marked defi-
ciency of EPO, iron deficiency, inflammations, blood
losses, bone marrow fibrosis, and aluminium overload,
certainly play additional role.
At baseline, the uremic state of the enrolled patients
was actually minimized by preexisting multiple pharma-
cologic and dietetic interventions. Further benefits of a
more severe protein restriction became manifest even
in this setting of adequate management of CRF. VLPD,
in fact, was not coupled with the relentless decline of
measured creatinine clearance, that, on the contrary, was
detected in the group randomized at LPD; this phenome-
non certainly contributed to postponing the initiation of
hemodialysis treatment in this small group of patients.
Of note, the MDRD Study, that is, the largest trial ad-
dressing this issue, led to a similar conclusion only in the
secondary analysis of the data [29]; this was possibly due
to the slight difference (less than 0.1 g/kg body weight/
day) in the mean achieved protein intake in LPD and
VLPD groups. Conversely, in our study, such a differ-
ence was on average of 0.3 g/kg body weight/day. On
this regard, it is important to underline that since protein
restricted diets represent a major change in lifestyle,
patients often show an imperfect compliance [30]. Never-
theless, on the basis of MDRD findings [29], other previ-
ous studies [14, 16], and the present work as well, it
is reasonable to recommend a well-designed protein-
restricted diet even if the compliance will be not optimal
because of the favorable effects on dialysis requirement,
nutritional status, anemia management, and hyperpara-
thyroidism.
Of note, our study also suggests a role of salt intake
on CRF progression. At variance with the previous
works on this issue, in fact, we measured urinary sodium
excretion; this index of sodium intake significantly de-
creased during VLPD, while it remained unchanged in
controls. Experimental studies have shown that salt re-
striction slows the progression of renal failure by directly
inhibiting glomerular hypertrophy [31, 32]. Our group
has previously suggested, by means of a retrospective
long-term study, a beneficial effect of low salt diet on
the rate of glomerular filtration rate (GFR) decline in
CRF patients [33]. Furthermore, a reduced salt intake
allows an improved control of blood pressure in CRF
[34]. Overall, the previous and the present findings may
indicate that a lower salt intake, which is invariably cou-
pled with protein restriction [33], may contribute to slow-
ing CRF progression by antihypertrophic and antihyper-
tensive effects.
CONCLUSION
This study provides first-time evidence that in patients
with advanced CRF and without recognized conditions
of EPO resistance, an effective decrease of dietary pro-
tein intake of 0.3 g/kg body weight/day, obtained by
means of supplemented VLPD, induces a progressive
reduction of about 35% of the EPO dose required to
maintain the target hemoglobin levels. This effect ap-
pears dependent on the correction of the moderate sec-
ondary hyperparathyroidism rather than on the reduc-
tion of plasma urea levels. The increase of responsiveness
to EPO, together with the delayed beginning of hemodi-
alysis treatment, undoubtedly represent a money-saving
feature of dietary protein restriction.
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